Pharmadrug Inc.
Pharmadrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.
Pharmadrug Inc. (PHRX)
Pharmadrug Inc. (PHRX)
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| Desjardins Securities Inc. | 79,000 | 0.01 | 0.015 | 149,000 | Scotia Capital Inc. |
| TD Securities Inc. | 20,000 | 0.01 | 0.015 | 31,000 | TD Securities Inc. |
| TD Securities Inc. | 15,000 | 0.01 | 0.02 | 72,000 | RBC Capital Markets |
| Desjardins Securities Inc. | 60,000 | 0.01 | 0.02 | 20,000 | National Bank Financial Inc. |
| TD Securities Inc. | 100,000 | 0.01 | 0.02 | 51,000 | TD Securities Inc. |
| TD Securities Inc. | 40,000 | 0.01 | 0.02 | 100,000 | TD Securities Inc. |
| TD Securities Inc. | 20,000 | 0.01 | 0.02 | 16,000 | TD Securities Inc. |
| TD Securities Inc. | 50,000 | 0.01 | 0.02 | 52,000 | BMO Nesbitt Burns Inc. |
| TD Securities Inc. | 500,000 | 0.01 | 0.02 | 16,000 | TD Securities Inc. |
| TD Securities Inc. | 200,000 | 0.01 | 0.02 | 8,000 | TD Securities Inc. |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| Anonymous | 200,000 | 0.01 | 0.02 | 3,000 | Anonymous |
| Anonymous | 20,000 | 0.01 | 0.00 | 0 | |
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 30 | 1,839,000 | 0.01 | 0.015 | 180,000 | 2 |
| 16 | 1,580,000 | 0.005 | 0.02 | 808,000 | 22 |
| 0 | 0 | 0.00 | 0.025 | 599,000 | 9 |
| 0 | 0 | 0.00 | 0.03 | 179,000 | 6 |
| 0 | 0 | 0.00 | 0.035 | 175,000 | 6 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 2 | 220,000 | 0.01 | 0.02 | 3,000 | 1 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Mar 14, 19:51 | 0.015 | 0.00 | 6,000 | Scotia Capital Inc. | Questrade Inc. | CSE |
| Mar 14, 16:53 | 0.015 | 0.00 | 1,000 | Scotia Capital Inc. | Questrade Inc. | CSE |
| Mar 14, 15:31 | 0.015 | 0.00 | 40,000 | Scotia Capital Inc. | Scotia Capital Inc. | CSE |
| Mar 14, 13:47 | 0.015 | 0.00 | 6,000 | Scotia Capital Inc. | National Bank Financial Inc. | CSE |
| Mar 13, 14:02 | 0.015 | 0.00 | 59,000 | TD Securities Inc. | Scotia Capital Inc. | CSE |
Company Info
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2023-1038 – Consolidation - Pharmadrug Inc. (PHRX)
le 20 octobre/October 2023
Pharmadrug Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every seven (7) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 51,518,049 common shares.
The name and symbol will not change.
